Evaluating blood tests for diagnosing metastatic uveal melanoma
Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
This study is testing if blood tests can help find advanced uveal melanoma earlier than regular scans, which could lead to better treatment options for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Sex | All |
| Sponsor | Hadassah Medical Organization Academic / other |
| Locations | 1 site (Jerusalem) |
| Trial ID | NCT01438658 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with uveal melanoma, the most common primary intraocular tumor in adults. It aims to assess the effectiveness of serum biomarkers in detecting metastatic disease earlier than traditional imaging methods. By monitoring changes in biomarker levels, the study seeks to identify metastases that could be surgically excised, potentially extending patient survival significantly. The hypothesis is that these biomarkers may indicate the presence of metastases through changes in their levels due to tumor activity or its environment.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with uveal melanoma.
Not a fit: Patients who refuse to participate in the study will not benefit from the findings.
Why it matters
Potential benefit: If successful, this approach could lead to earlier diagnosis and treatment of metastatic uveal melanoma, significantly improving patient survival rates.
How similar studies have performed: While the use of serum biomarkers in oncology is established, the specific application to metastatic uveal melanoma is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of uveal melanoma Exclusion Criteria: * refusal to participate in the study
Where this trial is running
Jerusalem
- Specialized Ocular Oncology Service, Hadassah-Hebrew-University Medical Center — Jerusalem, Israel (Recruiting)
Study contacts
- Principal investigator: Shahar Frenkel, MD, PhD — Hadassah Medical Organization
- Study coordinator: Shahar Frenkel, MD, PhD
- Email: shahar@hadassah.org.il
- Phone: +972-2-6776579
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.